Delving into the Latest Updates on Beijing Chigenovo Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Gene therapy	3
AAV based gene therapy	2
Gene editing	2

Top 5 Target	Count

CYP4V2(cytochrome P450 family 4 subfamily V member 2)	1
RPGR(X-linked retinitis pigmentosa GTPase regulator)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

Preclinical

IND Approval

1

Phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ZVS-101e ( CYP4V2 )	Bietti Crystalline Dystrophy More	Phase 3
ZVS-203e ( RP4 )	Retinitis Pigmentosa More	IND Approval
ZVC-105e	Retinitis Pigmentosa More	Preclinical
ZVS-204e	Retinitis Pigmentosa More	Preclinical
ZVS-106e	Stargardt Disease More	Preclinical